Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colesevelam in Pediatric Heterozygous Familial Hypercholesterolemia
NCT00145574Phase 4Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2005
- Primary completion
- Dec 2007
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 8
01
Overview
Phase 4, randomised, double-blind trial of colesevelam in heterozygous familial hypercholesterolemia (HeFH) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Percent Change in Plasma Low Density Lipoprotein-cholesterol at 8 weeks. Started Nov 2005; status: completed.
02
Drugs
colesevelam
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT00145574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00145574.